Renal tubulointerstitial expansion is associated with endothelial dysfunction and inflammation in type 1 diabetes

Scandinavian Journal of Clinical and Laboratory Investigation

Volumn 69, Issue 1, 2009, Pages 138-144

  Bangstad, Hans Jacob ^a,c,d   Seljeflot, Ingebjørg ^a,d   Berg, Tore J ^b,c,d   Hanssen, Kristian F ^b,c,d  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^b AKER UNIVERSITY HOSPITAL   (Norway)

^c Aker and Ulleval Diabetes Research Centre   (Norway)

^d UNIVERSITY OF OSLO   (Norway)

Author keywords

Cytokines; Diabetic nephropathy; Endothelial dysfunction; Inflammation; Microalbuminuria; PAI 1; Quantitative morphology; Tubulointerstitium

Indexed keywords

ALBUMIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CYTOKINE; HEMOGLOBIN A1C; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; INTERLEUKIN 8; N(G),N(G) DIMETHYLARGININE; PLASMINOGEN ACTIVATOR INHIBITOR; REACTIVE OXYGEN METABOLITE; TISSUE PLASMINOGEN ACTIVATOR; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; BLADDER CAPACITY; CELL ACTIVATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; COVARIANCE; DIABETIC NEPHROPATHY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE DURATION; DISEASE MARKER; ENDOTHELIAL DYSFUNCTION; ENZYME ACTIVITY; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; INDEPENDENT VARIABLE; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; INTERSTITIAL FLUID; INTERSTITIAL NEPHRITIS; KIDNEY INTERSTITIUM; KIDNEY TUBULE; MALE; MICROALBUMINURIA; MORPHOMETRICS; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUANTITATIVE ASSAY; URINARY EXCRETION;

EID: 61649095683     PISSN: 00365513     EISSN: 15027686     Source Type: Journal    
DOI: 10.1080/00365510802444080     Document Type: Conference Paper

References (29)

1. Gilbert RE, Cooper ME. The tubulointerstitium in progressive diabetic kidney disease: more than an aftermath of glomerular injury? Kidney Int 1999;56:1627-37.
2. Wolf G, Ziyadeh FN. Molecular mechanisms of diabetic renal hypertrophy. Kidney Int 1999;56:393-405.
3. Osterby R, Bangstad HJ, Rudberg S. Follow-up study of glomerular dimensions and cortical interstitium in microalbuminuric type 1 diabetic patients with or without antihypertensive treatment. Nephrol Dial Transplant 2000;15:1609-16.
4. Pecoits-Filho R, Heimburger O, Barany P, Suliman M, Fehrman-Ekholm I, Lindholm B, Stenvinkel P. Associations between circulating inflammatory markers and residual renal function in CRF patients. Am J Kidney Dis 2003;41:1212-18.
5. Navarro JF, Mora C. Role of inflammation in diabetic complications. Nephrol Dial Transpl 2005;20:2601-4.
6. Bangstad HJ, Osterby R, Dahl-Jorgensen K, Berg KJ, Hartmann A, Hanssen KF. Improvement of blood glucose control in IDDM patients retards the progression of morphological changes in early diabetic nephropathy. Diabetologia 1994;37:483-90.
7. Bangstad HJ, Osterby R, Rudberg S, Hartmann A, Brabrand K, Hanssen KF. Kidney function and glomerulopathy over 8 years in young patients with Type I (insulin-dependent) diabetes mellitus and microalbuminuria. Diabetologia 2002;45:253-61.
8. Eid HM, Eritsland J, Larsen J, Arnesen H, Seljeflot I. Increased levels of asymmetric dimethylarginine in populations at risk for atherosclerotic disease. Effects of pravastatin. Atherosclerosis 2003;166:279-84.
9. Bangstad HJ, Osterby R, Dahl-Jorgensen K, Berg KJ, Hartmann A, Nyberg G, Frahm BS, Hanssen KF. Early glomerulopathy is present in young, type 1 (insulin-dependent) diabetic patients with microalbuminuria. Diabetologia 1993;36:523-9.
10. Lane PH, Steffes MW, Fioretto P, Mauer SM. Renal interstitial expansion in insulin-dependent diabetes mellitus. Kidney Int 1993;43:661-7.
11. Drummond K, Mauer M. The early natural history of nephropathy in type 1 diabetes: II. Early renal structural changes in type 1 diabetes. Diabetes 2002;51:1580-7.
12. Ma LJ, Yang H, Gaspert A, Gaspert A, Carlesso G, Barty MM, Davidson JM, Sheppard D, Fogo AB. Transforming growth factor-beta-dependent and -independent pathways of induction of tubulointerstitial fibrosis in beta6(-/-) mice. Am J Pathol 2003;163:1261-73.
13. Fogo AB. Progression versus regression of chronic kidney disease. Nephrol Dial Transpl 2006;21:281-4.
14. Eddy AA, Fogo AB. Plasminogen activator inhibitor-1 in chronic kidney disease: evidence and mechanisms of action. J Am Soc Nephrol 2006;17:2999-3012.
15. Seljeflot I, Larsen JR, Dahl-Jorgensen K, Hanssen KF, Arnesen H. Fibrinolytic activity is highly influenced by long-term glycemic control in Type 1 diabetic patients. J Thromb Haemost 2006;4:686-8.
16. Ziyadeh FN. Mediators of diabetic renal disease: the case for tgf-Beta as the major mediator. J Am Soc Nephrol 2004;15 Suppl 1:S55-7.
17. Eddy AA. Plasminogen activator inhibitor-1 and the kidney. Am J Physiol Renal Physiol 2002;283:F209-20.
18. Fogo AB. Renal fibrosis: not just PAI-1 in the sky. J Clin Invest 2003;112:326-8.
19. Fliser D, Kronenberg F, Kielstein JT, Morath C, Bode-Boger SM, Haller H, Ritz E. Asymmetric dimethylarginine and progression of chronic kidney disease: the mild to moderate kidney disease study. J Am Soc Nephrol 2005;16:2456-61.
20. Tarnow L, Hovind P, Teerlink T, Stehouwer CD, Parving HH. Elevated plasma asymmetric dimethylarginine as a marker of cardiovascular morbidity in early diabetic nephropathy in type 1 diabetes. Diabetes Care 2004;27:765-9.
21. Kielstein JT, Boger RH, Bode-Boger SM, Frölich JC, Haller H, Ritz E, Fliser D. Marked increase of asymmetric dimethylarginine in patients with incipient primary chronic renal disease. J Am Soc Nephrol 2002;13:170-6.
22. Altinova AE, Arslan M, Sepici-Dincel A, Akturk M, Altan N, Toruner FB. Uncomplicated type 1 diabetes is associated with increased asymmetric dimethylarginine concentrations. J Clin Endocrinol Metab 2007;92:1881-5.
23. Chan NN, Chan JC. Asymmetric dimethylarginine (ADMA): a potential link between endothelial dysfunction and cardiovascular diseases in insulin resistance syndrome? Diabetologia 2002;45:1609-16.
24. Glowinska B, Urban M, Peczynska J, Florys B. Soluble adhesion molecules (sICAM-1, sVCAM-1) and selectins (sE selectin, sP selectin, sL selectin) levels in children and adolescents with obesity, hypertension, anddiabetes. Metabolism 2005;54:1020-6.
25. Clausen P, Jacobsen P, Rossing K, Jensen JS, Parving HH, Feldt-Rasmussen B. Plasma concentrations of VCAM-1 and ICAM-1 are elevated in patients with Type 1 diabetes mellitus with microalbuminuria and overt nephropathy. Diabetes Med 2000;17:644-9.
26. Navarro JF, Milena FJ, Mora C, Leon C, Claverie F, Flores C, Garcia J. Tumor necrosis factor-alpha gene expression in diabetic nephropathy: relationship with urinary albumin excretion and effect of angiotensin-converting enzyme inhibition. Kidney Int 2005;68:S98-102.
27. Mauer SM, Steffes MW, Ellis EN, Sutherland DE, Brown DM, Goetz FC. Structural-functional relationships in diabetic nephropathy. J Clin Invest 1984;74:1143-55.
28. Fogo AB. Mechanisms of progression of chronic kidney disease. Pediatr Nephrol 2007;22:2011-22.
29. Taft JL, Nolan CJ, Yeung SP, Hewitson TD, Martin FI. Clinical and histological correlations of decline in renal function in diabetic patients with proteinuria. Diabetes 1994;43:1046-51.